185 related articles for article (PubMed ID: 37288833)
1. Impact of thoracic tumor radiotherapy on survival in non-small-cell lung cancer with malignant pleural effusion treated with targeted therapy: Propensity score matching study.
Li Q; Hu C; Su S; Ma Z; Geng Y; Hu Y; Jin H; Li H; Lu B
Cancer Med; 2023 Jul; 12(14):14949-14959. PubMed ID: 37288833
[TBL] [Abstract][Full Text] [Related]
2. Non-Small Cell Lung Cancer with Malignant Pleural Effusion May Require Primary Tumor Radiotherapy in Addition to Drug Treatment.
Li Q; Hu C; Su S; Ma Z; Geng Y; Hu Y; Li H; Lu B
Cancer Manag Res; 2022; 14():3347-3358. PubMed ID: 36465711
[TBL] [Abstract][Full Text] [Related]
3. Risk Factors for and Time to Recurrence of Symptomatic Malignant Pleural Effusion in Patients With Metastatic Non-Small Cell Lung Cancer with EGFR or ALK Mutations.
Schwalk AJ; Ost DE; Saltijeral SN; De La Garza H; Casal RF; Jimenez CA; Eapen GA; Lewis J; Rinsurongkawong W; Rinsurongkawong V; Lee J; Elamin Y; Zhang J; Roth JA; Swisher S; Heymach JV; Grosu HB
Chest; 2021 Mar; 159(3):1256-1264. PubMed ID: 33217413
[TBL] [Abstract][Full Text] [Related]
4. The prognosis after contraindicated surgery of NSCLC patients with malignant pleural effusion (M1a) may be better than expected.
Ren Y; Dai C; Shen J; Liu Y; Xie D; Zheng H; He J; Liang W; Jiang G; Fei K; Yang P; He J; Chen C
Oncotarget; 2016 May; 7(18):26856-65. PubMed ID: 27057627
[TBL] [Abstract][Full Text] [Related]
5. Treatment outcome comparisons between exons 19 and 21 EGFR mutations for non-small-cell lung cancer patients with malignant pleural effusion after first-line and second-line tyrosine kinase inhibitors.
Zheng Z; Xie D; Su H; Lin B; Zhao L; Deng X; Chen H; Fei S; Jin X; Xie C
Tumour Biol; 2017 Jun; 39(6):1010428317706211. PubMed ID: 28618947
[TBL] [Abstract][Full Text] [Related]
6. Intrapleural staphylococcal superantigen induces resolution of malignant pleural effusions and a survival benefit in non-small cell lung cancer.
Ren S; Terman DS; Bohach G; Silvers A; Hansen C; Colt H; Sahn SA
Chest; 2004 Nov; 126(5):1529-39. PubMed ID: 15539723
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab plus chemotherapy in nonsquamous non-small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: A phase II study North East Japan Study group trial NEJ013B.
Noro R; Kobayashi K; Usuki J; Yomota M; Nishitsuji M; Shimokawa T; Ando M; Hino M; Hagiwara K; Miyanaga A; Seike M; Kubota K; Gemma A;
Thorac Cancer; 2020 Jul; 11(7):1876-1884. PubMed ID: 32421226
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of malignant pleural effusion at presentation in patients with metastatic non-small-cell lung cancer.
Morgensztern D; Waqar S; Subramanian J; Trinkaus K; Govindan R
J Thorac Oncol; 2012 Oct; 7(10):1485-9. PubMed ID: 22982649
[TBL] [Abstract][Full Text] [Related]
9. Detecting EGFR mutations and ALK/ROS1 rearrangements in non-small cell lung cancer using malignant pleural effusion samples.
Yao Y; Peng M; Shen Q; Hu Q; Gong H; Li Q; Zheng Z; Xu B; Li Y; Dong Y
Thorac Cancer; 2019 Feb; 10(2):193-202. PubMed ID: 30565433
[TBL] [Abstract][Full Text] [Related]
10. Molecular Profiling of Malignant Pleural Effusion in Metastatic Non-Small-Cell Lung Carcinoma. The Effect of Preanalytical Factors.
Carter J; Miller JA; Feller-Kopman D; Ettinger D; Sidransky D; Maleki Z
Ann Am Thorac Soc; 2017 Jul; 14(7):1169-1176. PubMed ID: 28557526
[TBL] [Abstract][Full Text] [Related]
11. Failure pattern and radiotherapy exploration in malignant pleural effusion non-small cell lung cancer treated with targeted therapy.
Li Q; Hu C; Su S; Ma Z; Geng Y; Hu Y; Li H; Lu B
Front Oncol; 2023; 13():974735. PubMed ID: 37274290
[TBL] [Abstract][Full Text] [Related]
12. [Comparative study of video-assisted thoracoscopic surgery vs thoracic tube drainage in synthetic therapy for malignant pleural effusion secondary to non-small cell lung cancer].
Gu LJ; Wang WJ
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Jul; 26(7):1023-6. PubMed ID: 16864104
[TBL] [Abstract][Full Text] [Related]
13. Previous Radiotherapy Increases the Efficacy of IL-2 in Malignant Pleural Effusion: Potential Evidence of a Radio-Memory Effect?
Chen D; Song X; Wang H; Gao Z; Meng W; Chen S; Ma Y; Wang Y; Li K; Yu J; Yue J
Front Immunol; 2018; 9():2916. PubMed ID: 30619280
[TBL] [Abstract][Full Text] [Related]
14. Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases.
Mak KS; Gainor JF; Niemierko A; Oh KS; Willers H; Choi NC; Loeffler JS; Sequist LV; Shaw AT; Shih HA
Neuro Oncol; 2015 Feb; 17(2):296-302. PubMed ID: 25053852
[TBL] [Abstract][Full Text] [Related]
15. Primary tumor resection of non-small cell lung cancer patients with ipsilateral pleural dissemination (M1a) in the era of targeted therapy.
Li H; Liu T; Sun Z; Yang F
Thorac Cancer; 2020 Nov; 11(11):3213-3222. PubMed ID: 32946207
[TBL] [Abstract][Full Text] [Related]
16. Symptomatic Radiation Pneumonitis in NSCLC Patients Receiving EGFR-TKIs and Concurrent Once-daily Thoracic Radiotherapy: Predicting the Value of Clinical and Dose-volume Histogram Parameters.
Yang X; Mei T; Yu M; Gong Y
Zhongguo Fei Ai Za Zhi; 2022 Jun; 25(6):409-419. PubMed ID: 35747920
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic and prognostic values of endothelial-cell-specific molecule-1 with malignant pleural effusions in patients with non-small cell lung cancer.
Lu GJ; Shao CJ; Zhang Y; Wei YY; Xie WP; Kong H
Oncotarget; 2017 Jul; 8(30):49217-49223. PubMed ID: 28514746
[TBL] [Abstract][Full Text] [Related]
18. Development and validation of the CAIL prognostic score in non-small cell lung cancer patients with malignant pleural effusion.
Li T; Tian P; Huang Q; Zeng H; Wei Q; Li Y
Clin Respir J; 2023 Nov; 17(11):1158-1168. PubMed ID: 37723659
[TBL] [Abstract][Full Text] [Related]
19. Primary tumour resection showed survival benefits for non-small-cell lung cancers with unexpected malignant pleural dissemination.
Ren YJ; She YL; Dai CY; Jiang GN; Fei K; Chen C
Interact Cardiovasc Thorac Surg; 2016 Mar; 22(3):321-6. PubMed ID: 26705302
[TBL] [Abstract][Full Text] [Related]
20. Malignant pleural effusion cell blocks are substitutes for tissue in EML4-ALK rearrangement detection in patients with advanced non-small-cell lung cancer.
Zhong J; Li X; Bai H; Zhao J; Wang Z; Duan J; An T; Wu M; Wang Y; Wang S; Wang J
Cytopathology; 2016 Dec; 27(6):433-443. PubMed ID: 27060609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
